Cerulean raises $24 million series C to fund nanodrug pipeline
This article was originally published in Scrip
Nanopharmaceuticals-focused Cerulean Pharma has closed a $24 million series C financing led by new investor Lilly Ventures. All existing investors, including Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners, also participated. The company plans to use the financing proceeds to advance its
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.